Skip to main content
ASCPT 2025 Annual Meeting Main banner

Sandra A. Visser, PhD (she/her/hers)

SVP, Head of Therapeutics Development
Alltrna

Sandra Visser, Ph.D., brings over two decades of extensive experience in quantitative medicine and strategic drug discovery and development with a passion to accelerate the development of novel therapies and improve patient outcomes. She is currently Head of Therapeutics Development at Alltrna.
Prior to Alltrna, Sandra has held leadership roles in leading pharmaceutical companies, including GSK, Merck, and AstraZeneca, where she and her teams successfully advanced preclinical and clinical drug projects and supported several successful marketing applications, using clinical and quantitative translational pharmacology concepts across diverse therapeutic areas, including oncology, cardiometabolic, and neuroscience.
Through her career, she has been recognized for her pivotal contributions to model informed drug discovery and development (MID3) and the integration of biomarker data into mathematical models to optimize dose selection, accelerate clinical trial design, and enhance regulatory submissions.
She is the incoming President of the American Society of Clinical Pharmacology and Therapeutics.
Sandra earned her M.Sc. in Bio-Pharmaceutical Sciences and Ph.D. in Quantitative Pharmacology from Leiden University in the Netherlands. She has published over 65 peer-reviewed scientific articles and has been an editor and reviewer for several scientific journals.

Presentation(s):